DK0624596T3 - Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler - Google Patents

Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler

Info

Publication number
DK0624596T3
DK0624596T3 DK94106848T DK94106848T DK0624596T3 DK 0624596 T3 DK0624596 T3 DK 0624596T3 DK 94106848 T DK94106848 T DK 94106848T DK 94106848 T DK94106848 T DK 94106848T DK 0624596 T3 DK0624596 T3 DK 0624596T3
Authority
DK
Denmark
Prior art keywords
compounds
preparation
drugs
bile acids
tetrazole derivatives
Prior art date
Application number
DK94106848T
Other languages
Danish (da)
English (en)
Inventor
Heiner Dr Glombik
Alfons Dr Enhsen
Werner Dr Dr Kramer
Guenter Dr Wess
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0624596T3 publication Critical patent/DK0624596T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK94106848T 1993-05-08 1994-05-02 Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler DK0624596T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4315368 1993-05-08

Publications (1)

Publication Number Publication Date
DK0624596T3 true DK0624596T3 (da) 1998-10-07

Family

ID=6487579

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94106848T DK0624596T3 (da) 1993-05-08 1994-05-02 Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler

Country Status (19)

Country Link
US (1) US5466815A (enExample)
EP (1) EP0624596B1 (enExample)
JP (1) JP3476157B2 (enExample)
KR (1) KR100333149B1 (enExample)
AT (1) ATE163938T1 (enExample)
AU (1) AU666440B2 (enExample)
CA (1) CA2123048C (enExample)
CY (1) CY2119B1 (enExample)
CZ (1) CZ289515B6 (enExample)
DE (1) DE59405410D1 (enExample)
DK (1) DK0624596T3 (enExample)
ES (1) ES2115096T3 (enExample)
FI (1) FI942075L (enExample)
GR (1) GR3026496T3 (enExample)
HU (1) HU217439B (enExample)
IL (1) IL109581A (enExample)
NO (1) NO304795B1 (enExample)
NZ (1) NZ260469A (enExample)
TW (1) TW289757B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (enExample) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US6323190B1 (en) 1998-07-31 2001-11-27 The Univeristy Of Georgia Research Foundation, Inc. Estrogen mimetics lacking reproductive tract effects
JP2002543216A (ja) 1999-04-30 2002-12-17 アーチ ディベロップメント コーポレイション ステロイド誘導体
US7086134B2 (en) * 2000-08-07 2006-08-08 Shipley Company, L.L.C. Alignment apparatus and method for aligning stacked devices
WO2002062302A2 (en) * 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
JP4309661B2 (ja) * 2001-05-03 2009-08-05 ザ ユニバーシティー オブ シカゴ 肝臓ｘ受容体
US6816317B2 (en) * 2002-01-31 2004-11-09 Lightel Technologies Inc. Collimator for ready fitting to an optical device with precise optical alignment without need for adjusting positions or angles to compensate for offsets or deviations during optical device assembly and method of making same
AU2003228485A1 (en) * 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
US7960439B1 (en) 2006-06-12 2011-06-14 Iowa State University Research Foundation, Inc. Environmentally sensitive foldable oligomers
JP2013500986A (ja) * 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
BR112017009657A2 (pt) 2014-11-06 2018-01-23 Enanta Pharmaceuticals, Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
RU2017121457A (ru) * 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2016219266A1 (en) * 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
WO2016173397A1 (zh) * 2015-04-28 2016-11-03 上海翰森生物医药科技有限公司 胆酸衍生物及其制备方法和医药用途
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
CA3011595C (en) 2016-02-09 2024-01-02 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
MX388300B (es) 2017-04-07 2025-03-19 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
CN113301901B (zh) * 2019-01-14 2022-09-09 北京轩义医药科技有限公司 四唑啉酮取代的类固醇及其用途
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
WO2020190358A1 (en) * 2019-03-19 2020-09-24 Siemens Healthcare Diagnostics Inc. Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158195A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
JP7665621B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh) 2021-06-03 2024-01-16 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN119053330A (zh) 2022-04-22 2024-11-29 阿尔比里奥公司 皮下给药asbt抑制剂
US20250368678A1 (en) * 2022-06-09 2025-12-04 Shandong Luye Pharmaceutical Co., Ltd. 19-nor-c3,3-disubstituted c21-azacyclo-substituted steroid and method for using same
EP4536232A1 (en) 2022-06-09 2025-04-16 Albireo AB Treating hepatitis
CN119487013A (zh) 2022-07-05 2025-02-18 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4629997A1 (en) 2022-12-09 2025-10-15 Albireo AB Asbt inhibitors in the treatment of renal diseases
CN122341622A (zh) * 2023-12-08 2026-07-03 山东绿叶制药有限公司 一种gabaa受体调节剂的晶型及其制备方法和应用
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5250524A (en) * 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals

Also Published As

Publication number Publication date
US5466815A (en) 1995-11-14
GR3026496T3 (en) 1998-07-31
CZ289515B6 (cs) 2002-02-13
AU666440B2 (en) 1996-02-08
TW289757B (enExample) 1996-11-01
NZ260469A (en) 1995-03-28
CZ113594A3 (en) 1994-12-15
IL109581A (en) 1998-03-10
NO941677D0 (no) 1994-05-06
HU9401443D0 (en) 1994-08-29
CA2123048A1 (en) 1994-11-09
HU217439B (hu) 2000-01-28
CA2123048C (en) 2005-11-29
FI942075A7 (fi) 1994-11-09
EP0624596A3 (de) 1995-06-07
ATE163938T1 (de) 1998-03-15
JPH06329695A (ja) 1994-11-29
DE59405410D1 (de) 1998-04-16
KR100333149B1 (ko) 2002-09-19
JP3476157B2 (ja) 2003-12-10
FI942075L (fi) 1994-11-09
ES2115096T3 (es) 1998-06-16
HUT67390A (en) 1995-04-28
IL109581A0 (en) 1994-08-26
EP0624596A2 (de) 1994-11-17
AU6194794A (en) 1994-11-10
NO304795B1 (no) 1999-02-15
FI942075A0 (fi) 1994-05-05
CY2119B1 (en) 2002-04-26
NO941677L (no) 1994-11-09
EP0624596B1 (de) 1998-03-11

Similar Documents

Publication Publication Date Title
NO941677L (no) Tetrazolderivater av gallesyrer, fremgangsmåter for fremstilling og deres anvendelse som legemiddel
DK0624594T3 (da) Monomere galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemiddel
DK0624595T3 (da) Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
FI883249A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-desmetyylimevalonihappojohdannaisten valmistamiseksi
DK0573848T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
FI96204C (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
DK383388D0 (da) 3-demethyl-4-fluor-mevalonsyrederivater, deres fremstilling, farmaceutiske praeparater deraf, deres anvendelse og mellemprodukter til deres fremstilling
ATE30719T1 (de) Imino-2-pyrrolidine, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
AU1264488A (en) Substituted pyridine-2,4-dicarboxylic acid derivatives, processes for their preparation, the use thereof and medicaments based on these compounds
ATE169023T1 (de) 2-spirocyclopropyl 4-acylcephalosporine und verfahren zu ihrer herstellung
IT1282286B1 (it) Seco-d steroidi sul sistema cardiovascolare, processi per la loro preparazione e composizioni farmaceutiche che li contengono.
ATE62688T1 (de) Benzylaminoaryl-dihydropyridinelactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.